Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2475 (LINC02475)
- Target
- LINC02475
- Molecular classification
- Long non-coding RNA (lncRNA), Other (non-protein coding RNA)
01
Overview
Long intergenic non-protein coding RNA 2475 (LINC02475), also known as liver cancer-associated transcript 1 (LVCAT1), is a long noncoding RNA identified as highly upregulated in hepatocellular carcinoma (HCC) compared to normal liver tissue, where its expression is virtually absent except for restricted presence in testis[1]. It functions as a cancer stemness-associated lncRNA, promoting tumor cell stemness, proliferation, metastasis via epithelial-mesenchymal transition, and resistance to both radiation and cisplatin chemotherapy. High LINC02475 expression is an independent negative prognostic indicator in HCC and serves as a potential biomarker for diagnosis and prognosis. Silencing LINC02475 suppresses tumorigenic pathways and enhances sensitivity to therapy, highlighting its utility as a therapeutic target and clinical biomarker for hepatocellular carcinoma[1][3].
- Other names
- LVCAT1liver cancer-associated transcript 1LINC02475
02
Mechanism of action
Not explicitly established for drugs, but silencing LINC02475 leads to suppression of stemness, proliferation, metastasis, and therapy resistance pathways in hepatocellular carcinoma cells
03
Biological functions
Regulation of cancer cell stemnessRegulation of cell proliferationRegulation of metastasis (epithelial-mesenchymal transition/EMT)Regulation of DNA replicationModulation of DNA damage repairModulation of radioresistanceModulation of chemoresistance
04
Disease associations
Cancer (notably hepatocellular carcinoma)
05
Safety considerations
No specific safety concerns directly reported, but as a novel biomarker, off-tumor expression, especially limited to testis, could be a consideration for translational therapies or biomarkers
06
Interacting drugs
No specific small molecule drugs or direct pharmacological agents reported to target LINC02475; observed modulation was through genetic silencing (e.g., RNA interference in experimental systems)
07
Biomarkers
Biomarker for diagnosis, prognosis, and progression of hepatocellular carcinomaDemonstrates high specificity for HCC compared to normal liver; minimal expression in non-tumor tissues except for restricted expression in normal testis
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 2475 (LINC02475).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2475 (LINC02475).